Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
Should Glaukos' (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors? [Yahoo! Finance]
Glaukos Corporation Q4 2025 Earnings Call Summary [Yahoo! Finance]
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $131.00 price target on the stock.
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.